A Single-Dose, Open Label, Randomized, Two-Way Crossover Pharmacokinetic Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Following Intake of Tablet Versus Capsule in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2014
At a glance
- Drugs Erdafitinib (Primary) ; JNJ 61818549
- Indications Lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 02 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.